---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-002736"
form_type: "8-K"
ticker: "SENS"
cik: "0001616543"
company_name: "Senseonics Holdings, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:52:47.698210+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Senseonics Q4 2025 preliminary revenue $14.2M (+71% YoY); FY2025 $35.2M; guides FY2026 $58-62M

## Summary
- Preliminary Q4 2025 revenue $14.2M (+71% YoY); FY2025 revenue $35.2M (+57% YoY); cash $94.3M.
- Patient base grew 103% in Q4 2025 vs Q4 2024; largest new patient addition in company history.
- Received FDA IDE approval to begin pivotal trial for self-powered Gemini sensor; first patients enrolled.
- 2026 revenue guidance $58-62M (65-76% growth); gross margin ~50%; commercial transition from Ascensia effective Jan 1, 2026.
- First commercial patients using pump partner Sequel's twiist insulin delivery system with Eversense 365 compatibility.

## SEC filing metadata
- accession: 0001104659-26-002736
- form_type: 8-K
- ticker: SENS
- cik: 0001616543
- company_name: Senseonics Holdings, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1616543/000110465926002736/0001104659-26-002736-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1616543/000110465926002736/tm262845d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-002736
- JSON: https://secwatch.observer/filing/0001104659-26-002736.json
- Plain text: https://secwatch.observer/filing/0001104659-26-002736.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.